46 related articles for article (PubMed ID: 9303581)
1. Arachidonic acid signaling is involved in the mechanism of imidazoline-induced KATP channel-independent stimulation of insulin secretion.
Sharoyko VV; Zaitseva II; Leibiger B; Efendić S; Berggren PO; Zaitsev SV
Cell Mol Life Sci; 2007 Nov; 64(22):2985-93. PubMed ID: 17922229
[TBL] [Abstract][Full Text] [Related]
2. Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site.
Kimura A; Tyacke RJ; Robinson JJ; Husbands SM; Minchin MC; Nutt DJ; Hudson AL
Brain Res; 2009 Jul; 1279():21-8. PubMed ID: 19410564
[TBL] [Abstract][Full Text] [Related]
3. Imidazoleacetic acid-ribotide: an endogenous ligand that stimulates imidazol(in)e receptors.
Prell GD; Martinelli GP; Holstein GR; Matulić-Adamić J; Watanabe KA; Chan SL; Morgan NG; Haxhiu MA; Ernsberger P
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13677-82. PubMed ID: 15365189
[TBL] [Abstract][Full Text] [Related]
4. Essential role of the imidazoline moiety in the insulinotropic effect but not the KATP channel-blocking effect of imidazolines; a comparison of the effects of efaroxan and its imidazole analogue, KU14R.
Bleck C; Wienbergen A; Rustenbeck I
Diabetologia; 2005 Dec; 48(12):2567-75. PubMed ID: 16283242
[TBL] [Abstract][Full Text] [Related]
5. Identification of the monomeric G-protein, Rhes, as an efaroxan-regulated protein in the pancreatic beta-cell.
Chan SL; Monks LK; Gao H; Deaville P; Morgan NG
Br J Pharmacol; 2002 May; 136(1):31-6. PubMed ID: 11976265
[TBL] [Abstract][Full Text] [Related]
6. Biological significance of agmatine, an endogenous ligand at imidazoline binding sites.
Raasch W; Schäfer U; Chun J; Dominiak P
Br J Pharmacol; 2001 Jul; 133(6):755-80. PubMed ID: 11454649
[No Abstract] [Full Text] [Related]
7. Multiple effector pathways regulate the insulin secretory response to the imidazoline RX871024 in isolated rat pancreatic islets.
Mourtada M; Chan SL; Smith SA; Morgan NG
Br J Pharmacol; 1999 Jul; 127(5):1279-87. PubMed ID: 10455276
[TBL] [Abstract][Full Text] [Related]
8. Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues?
Morgan NG; Chan SL
Curr Pharm Des; 2001 Sep; 7(14):1413-31. PubMed ID: 11472276
[TBL] [Abstract][Full Text] [Related]
9. Imidazoline binding sites and receptors in cardiovascular tissue.
Molderings GJ; Göthert M
Gen Pharmacol; 1999 Jan; 32(1):17-22. PubMed ID: 9888248
[TBL] [Abstract][Full Text] [Related]
10. Imidazoline/guanidinium binding sites and their relation to inhibition of K(ATP) channels in pancreatic B-cells.
Rustenbeck I; Herrmann C; Ratzka P; Hasselblatt A
Naunyn Schmiedebergs Arch Pharmacol; 1997 Sep; 356(3):410-7. PubMed ID: 9303581
[TBL] [Abstract][Full Text] [Related]
11. Imidazolines stimulate release of insulin from RIN-5AH cells independently from imidazoline I1 and I2 receptors.
Olmos G; Kulkarni RN; Haque M; MacDermot J
Eur J Pharmacol; 1994 Sep; 262(1-2):41-8. PubMed ID: 7813577
[TBL] [Abstract][Full Text] [Related]
12. Imidazolines and the pancreatic B-cell. Actions and binding sites.
Rustenbeck I; Köpp M; Ratzka P; Leupolt L; Hasselblatt A
Ann N Y Acad Sci; 1999 Jun; 881():229-40. PubMed ID: 10415921
[TBL] [Abstract][Full Text] [Related]
13. Imidazoline receptors in rat liver cells: a novel receptor or a subtype of alpha 2-adrenoceptors?
Zonnenchein R; Diamant S; Atlas D
Eur J Pharmacol; 1990 Nov; 190(1-2):203-15. PubMed ID: 1981751
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver.
Ozaita A; Olmos G; Boronat MA; Lizcano JM; Unzeta M; García-Sevilla JA
Br J Pharmacol; 1997 Jul; 121(5):901-12. PubMed ID: 9222546
[TBL] [Abstract][Full Text] [Related]
15. Presynaptic imidazoline receptors and non-adrenoceptor [3H]-idazoxan binding sites in human cardiovascular tissues.
Molderings GJ; Likungu J; Jakschik J; Göthert M
Br J Pharmacol; 1997 Sep; 122(1):43-50. PubMed ID: 9298527
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
